GELS Gelteq Limited Ordinary Shares
USHealthcareAs of 2026-07-09 12:58
Why GELS matters now
Gelteq Limited Ordinary Shares (GELS) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.53 with -5.47% on the session and $4.9M in market capitalization; recent performance reads 1-month +166.60% and YTD +30.00%.
The latest financial table shown here is FY 2025, with revenue of $165.6K, net income of $-6.6M, and EPS of $0.00. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -45.3%.
The latest indexable market news headline is "Gelteq Provides Corporate Update: Launching Veterinary and Human Clinical Trials, Pharmaceutical Pipeline Expanding Across Multiple Programs" from GlobeNewsWire.
Additional event context on this page matters because recent insider activity includes Givoni Nathan J filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.00
P/S
82.16
EV/EBITDA
-4.96
DCF Value
$-0.27
FCF Yield
-45.3%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-3317.7%
Net Margin
-4011.9%
ROE
-43.0%
ROA
-30.9%
ROIC
-27.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| FY 2025 | $165.6K | $-6.6M | $0.00 |
| Q4 2024 | $0.00 | $-1.1M | $0.00 |
| FY 2024 | $0.00 | $-3.5M | $0.00 |
| Q3 2024 | $0.00 | $-727.4K | $0.00 |
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
AU
Exchange
—
Beta
-0.18
Gelteq Limited, established in 2017 and based in Caulfield, Australia, specializes in creating and commercializing advanced gel-based delivery methods for both human and animal use. The company offers customizable, white-label gel formulations that can be applied to a broad array of goods, such as prescribed pharmaceuticals, non-prescription remedies, nutritional supplements (including sports-related products), and veterinary care items.